PE70698A1 - CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA - Google Patents
CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMAInfo
- Publication number
- PE70698A1 PE70698A1 PE1997000351A PE00035197A PE70698A1 PE 70698 A1 PE70698 A1 PE 70698A1 PE 1997000351 A PE1997000351 A PE 1997000351A PE 00035197 A PE00035197 A PE 00035197A PE 70698 A1 PE70698 A1 PE 70698A1
- Authority
- PE
- Peru
- Prior art keywords
- protein
- moles
- igg
- tnfo
- asthma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA PROTEINA CARACTERIZADA PORQUE LA PORCION SOLUBLE DE LA PROTEINA RECEPTORA DE TNF p55 SE ENCUENTRA UNIDA A UNA INMUNOGLOBULINA G (IgG), DE PREFERENCIA G1 HUMANA, EN DONDE DICHA IgG FUSIONADA CONTIENE TODOS LOS DOMINIOS DE LA IgG, EXCEPTO EL PRIMER DOMINIO DE IgG DE LA REGION CONSTANTE DE LA CADENA PESADA DE LA IgG. TAMBIEN SE REFIERE A LAS PREPARACIONES PURIFICADAS DEL TNFR-Ig, EXPRESADOS A PARTIR DE CULTIVOS QUE PRODUCEN LA PROTEINA, LA QUE ADEMAS ESTA UNIDA A OLIGOSACARIDOS QUE TERMINAN EN UNO O MAS RESIDUOS DE ACIDO SIALICO Y N-ACETILGLUCOSAMINA, EN DONDE DICHAS PREPARACIONES PURIFICADAS COMPRENDEN PROPORCIONES ESPECIFICAS DE: (a) ACIDO SIALICO, EN UNA RELACION MOLAR CON RESPECTO A LA PROTEINA DE 4 MOLES A 7 MOLES, Y (b) N-ACETIL-GLUCOSAMINA, EN UNA RELACION MOLAR CON RESPECTO A LA PROTEINA DE 1 MOL A 2 MOLES, ADEMAS PRESENTAN UN PUNTO ISOELECTRICO DE 5,5 A 7,5. LAS PROTEINAS DE FUSION DEL RECEPTOR DEL FACTOR DE NECROSIS TUMORAL (TNF) E IgG1, SOLUBLE RECOMBINANTE (TNFR-Ig) ACTUAN BLOQUEANDO LA ACCION DEL TNFO, SIENDO UTILES PARA ALIVIAR EL ASMAIT REFERS TO A PROTEIN CHARACTERIZED BECAUSE THE SOLUBLE PORTION OF THE TNF RECEPTOR PROTEIN p55 IS LINKED TO AN IMMUNOGLOBULIN G (IgG), WHERE SUCH FUSED IgG CONTAINS ALL THE DOMAINS OF THE FIRST OF THE CONSTANT REGION OF THE HEAVY CHAIN OF THE IgG. IT ALSO REFERS TO THE PURIFIED PREPARATIONS OF TNFR-Ig, EXPRESSED FROM CROPS THAT PRODUCE PROTEIN, WHICH ALSO IS LINKED TO OLIGOSACCHARIDES THAT END IN ONE OR MORE RESIDUES OF SALIC ACID AND N-ACETILGLUCOSAMINE, WHERE IN WHICH THEY ARE PRESIDIFIED SPECIFIC PROPORTIONS OF: (a) SIALIC ACID, IN A MOLAR RELATION WITH RESPECT TO THE PROTEIN OF 4 MOLES TO 7 MOLES, AND (b) N-ACETYL-GLUCOSAMINE, IN A MOLAR RELATION WITH RESPECT TO THE PROTEIN OF 1 MOL TO 2 MOLES, ALSO PRESENT AN ISOELECTRIC POINT OF 5.5 TO 7.5. THE TUMOR NECROSIS FACTOR RECEPTOR FUSION PROTEINS (TNF) AND IgG1, SOLUBLE RECOMBINANT (TNFR-Ig) ACT BY BLOCKING THE ACTION OF TNFO, BEING USEFUL TO RELIEF ASTHMA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1684296P | 1996-05-08 | 1996-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE70698A1 true PE70698A1 (en) | 1998-11-18 |
Family
ID=21779275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1997000351A PE70698A1 (en) | 1996-05-08 | 1997-05-05 | CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0910413A2 (en) |
JP (1) | JP2000510113A (en) |
KR (1) | KR20000010825A (en) |
CN (1) | CN1233189A (en) |
AR (1) | AR007020A1 (en) |
AU (1) | AU725408B2 (en) |
BR (1) | BR9708928A (en) |
CA (1) | CA2253557A1 (en) |
CO (1) | CO4820397A1 (en) |
HR (1) | HRP970224A2 (en) |
MA (1) | MA24169A1 (en) |
PE (1) | PE70698A1 (en) |
TR (1) | TR199802238T2 (en) |
WO (1) | WO1997041895A2 (en) |
ZA (1) | ZA973843B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1044267A2 (en) * | 1997-12-29 | 2000-10-18 | Regeneron Pharmaceuticals, Inc. | Novel nucleic acid and polypeptide with homology to the tnf-receptors |
TR200504220T2 (en) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins. |
US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
JP4980048B2 (en) * | 2003-02-28 | 2012-07-18 | アレス トレーディング ソシエテ アノニム | Liquid formulation of tumor necrosis factor binding protein |
TWI374935B (en) * | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
KR20090071652A (en) | 2006-10-20 | 2009-07-01 | 바이오겐 아이덱 엠에이 인코포레이티드 | Treatment of demyelinating disorders with soulble lymphotoxin-beta-receptor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1132471A3 (en) * | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-binding proteins |
WO1994006476A1 (en) * | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US5684222A (en) * | 1993-01-22 | 1997-11-04 | Ontario Cancer Institute | Mutant mouse having a disrupted TNFRp55 |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
JPH09508140A (en) * | 1994-07-22 | 1997-08-19 | エフ・ホフマン−ラ ロシュ アーゲー | Pharmaceutical composition containing chimeric TNF binding protein |
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
-
1997
- 1997-05-02 JP JP09539522A patent/JP2000510113A/en active Pending
- 1997-05-02 CN CN97194455A patent/CN1233189A/en active Pending
- 1997-05-02 WO PCT/EP1997/002256 patent/WO1997041895A2/en not_active Application Discontinuation
- 1997-05-02 EP EP97921849A patent/EP0910413A2/en not_active Withdrawn
- 1997-05-02 AU AU27764/97A patent/AU725408B2/en not_active Ceased
- 1997-05-02 BR BR9708928-1A patent/BR9708928A/en not_active Application Discontinuation
- 1997-05-02 MA MA24590A patent/MA24169A1/en unknown
- 1997-05-02 KR KR1019980708961A patent/KR20000010825A/en not_active Application Discontinuation
- 1997-05-02 HR HR60/016,842A patent/HRP970224A2/en not_active Application Discontinuation
- 1997-05-02 TR TR1998/02238T patent/TR199802238T2/en unknown
- 1997-05-02 CA CA002253557A patent/CA2253557A1/en not_active Abandoned
- 1997-05-05 PE PE1997000351A patent/PE70698A1/en not_active Application Discontinuation
- 1997-05-05 ZA ZA9703843A patent/ZA973843B/en unknown
- 1997-05-06 AR ARP970101876A patent/AR007020A1/en not_active Application Discontinuation
- 1997-05-07 CO CO97024335A patent/CO4820397A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2776497A (en) | 1997-11-26 |
HRP970224A2 (en) | 1998-04-30 |
AU725408B2 (en) | 2000-10-12 |
MA24169A1 (en) | 1997-12-31 |
CN1233189A (en) | 1999-10-27 |
BR9708928A (en) | 2000-05-09 |
WO1997041895A2 (en) | 1997-11-13 |
EP0910413A2 (en) | 1999-04-28 |
ZA973843B (en) | 1997-11-10 |
KR20000010825A (en) | 2000-02-25 |
JP2000510113A (en) | 2000-08-08 |
CA2253557A1 (en) | 1997-11-13 |
CO4820397A1 (en) | 1999-07-28 |
AR007020A1 (en) | 1999-10-13 |
WO1997041895A3 (en) | 1998-03-12 |
TR199802238T2 (en) | 1999-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Beck et al. | Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells | |
UY25897A1 (en) | PREPARATION OF FUSION PROTEINS WITH PORTIONS OF IMMUNOGLOBULINS | |
DE69227041D1 (en) | EXPRESSION AND CLEANING OF RECOMBINANT, SOLUBLE TISSUE FACTOR | |
ATE168415T1 (en) | WATER SOLUBLE PEPTIDE ANALOGUES WITH BINDING SITES | |
SE9100799D0 (en) | RECOMBINANT HUMAN FACTOR VIII DERIVATIVES | |
SE8904239L (en) | A RECOMBINATE, HUMAN FACTOR VIII DERIVATE | |
BG102983A (en) | Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application | |
AU8159394A (en) | Immunoconjugates | |
GR3036906T3 (en) | Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof. | |
ATE223229T1 (en) | COMPOSITIONS OF CONJUGATES OF THE STABLE, ACTIVE, HUMAN OB PROTEIN WITH THE FC CHAIN OF IMMUNOGLOBULINS AND RELATED METHODS | |
ATE168719T1 (en) | OSTEOGENIC PEPTIDES | |
PE70698A1 (en) | CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA | |
DK0871474T3 (en) | Human insulin generation | |
DE69030937D1 (en) | Interleukin-3 mutants | |
ATE164838T1 (en) | NEW PROPOXYPHENE DERIVATIVES AND THEIR PROTEIN AND POLYPEPTIDE LABELS AND CONJUGATES | |
PT833917E (en) | POLYPEPTIDIC MOLECULES OF THE PRE-ERYTHROCITARY STAGE OF MALARIA | |
CA2126182A1 (en) | Humanized antibodies reactive with gpiib/iiia | |
AU2002363465A1 (en) | Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4 | |
AU1444699A (en) | Single-chain polypeptides comprising troponin i and troponin | |
NO20011263D0 (en) | Moraxella Catarrhalis BASBO34 polypeptides and uses thereof | |
ATE317851T1 (en) | POLYPEPTIDES WITH AMINO ACID SEQUENCES FROM THE N-TERMINAL AREA OF GP116 OF CYTOMEGALOVIRUS AND THEIR USE IN DIAGNOSTICS, PROPHYLAXIS AND THERAPY | |
Wines et al. | The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues | |
ES2158235T3 (en) | ANTIGENIC PEPTIDES WITH SUBSTITUTIONS OF GLYCINE. | |
HUP0001579A2 (en) | Cell surface molecule mediating cell adhesion and signal transmission | |
IT1262550B (en) | Immunotoxins containing purified RIP proteins from Saponaria ocymoides and Vaccaria pyramidata |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |